Sareum Holdings PLC Research Update (5356T)
March 25 2021 - 9:07AM
UK Regulatory
TIDMSAR
RNS Number : 5356T
Sareum Holdings PLC
25 March 2021
SAREUM HOLDINGS PLC
("Sareum" or the "Company")
Sareum Notes SRA737 Combination Data to be Presented at the AACR
Annual Meeting
Cambridge, UK, 25 March 2021 - Sareum Holdings plc (AIM: SAR),
the specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and
autoimmune diseases, notes that researchers from the Institute of
Cancer Research (ICR) will present preclinical data on the
combination of the Chk1 inhibitor SRA737 with AstraZeneca's WEE1
inhibitor, adavosertib, at the forthcoming American Association for
Cancer Research (AACR) Annual Meeting.
SRA737 was discovered and initially developed by scientists at
The ICR in collaboration with Sareum, and with funding from Sareum
and Cancer Research UK. SRA737 was licensed by CRT Pioneer Fund
(CPF) to Sierra Oncology, in a c.$300 million plus royalties
licence deal, with Sareum eligible to receive 27.5% of all payments
to CPF under the agreement.
The poster* describes how the combination of SRA737 and
adavosertib potentiated cell death in cellular models of ovarian,
breast and pancreatic cancer and in disease model studies of
ovarian and breast cancer.
* "A study of combinatorial growth inhibition, cell death and
DNA damage repair caused by CHK1 inhibitor SRA737 and WEE1
inhibitor adavosertib in TP53 mutated cell lines" (Abstract 1010),
to be presented on-line during the "Cellular Responses to
Anticancer Drugs" session on 10 April 2021.
https://www.abstractsonline.com/pp8/#!/9325/presentation/2082
Sareum's CSO, Dr John Reader, commented: "We are encouraged to
see yet another potential treatment modality for SRA737, in this
case in tumours with a TP53 mutation, a mutation that is present in
approximately half of all solid tumour cancers."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / James Bellman 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce / John Beresford-Peirse 020 3764 2341
Citigate Dewe Rogerson (Financial
PR)
Mark Swallow/ David Dible 020 7638 9571
Notes for editors:
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RESFLFISVSIEFIL
(END) Dow Jones Newswires
March 25, 2021 10:07 ET (14:07 GMT)
Sareum (LSE:SAR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sareum (LSE:SAR)
Historical Stock Chart
From Apr 2023 to Apr 2024